Riboflavin is the B-vitamin that quietly runs your energy factories. Every molecule of ATP your mitochondria churn out depends on a chain of enzymes, and two of the most important links in that chain — Complex I and Complex II — need a yellow helper molecule called FAD, which your body builds only from riboflavin. That is why the first scientists to study riboflavin in the 1930s named it after its color (the Latin “flavus,” yellow). Nearly a century later, a group of nutrition researchers in Northern Ireland — led by Helene McNulty and her colleagues — discovered something the vitamin world had overlooked: a cheap, 1.6-milligram dose of riboflavin can lower blood pressure, but only in the roughly one in ten people born with two copies of a specific gene variant. Riboflavin’s story is a case study in why “just take a B-complex” is often the wrong advice — the dose that matters depends entirely on who you are.
📋 Simple Summary
Riboflavin, also called vitamin B2, is a water-soluble B-vitamin your body turns into two helper molecules — FAD and FMN — that power your mitochondria, the energy factories inside every cell. The evidence for it is real but narrow: high-dose riboflavin (400 mg a day) reduces migraine attacks in randomized trials, and a much smaller 1.6 mg a day lowers blood pressure and a harmful blood protein called homocysteine — but only in the roughly 10–12% of people who carry two copies of a common gene variant called MTHFR TT. For everyone else, extra riboflavin beyond what you get from food has almost no evidence of benefit, and it is not a longevity molecule like rapamycin. But deficiency is surprisingly common in older adults, and for the right person, riboflavin is one of the cheapest, safest, most targeted supplements in existence. This page explains exactly what the science shows, what dose to take, and who actually benefits.
The detailed breakdown continues below for those who want the full science.
Published: August 17, 2026
Evidence Tier: 🥈 Silver — 🥇 Gold for migraine prevention and 🥈 for gene-specific blood pressure lowering, but no general anti-aging proof
Category: 💊 Supplements & Compounds
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Strongest benefit: 400 mg/day cut migraine attack frequency in a randomized trial — 59% of people improved by half or more, versus 15% on placebo (NNT of 2.3).
- Gene-specific blood pressure: Just 1.6 mg/day lowered systolic blood pressure by up to 9.2 mmHg in people with the MTHFR 677TT genotype.
- Essential, and deficiency is common: About 30% of older adults have low riboflavin status, and it is required for mitochondrial energy and antioxidant recycling.
- Extraordinary safety: Water-soluble and non-toxic — excess is simply excreted as harmless bright-yellow urine.
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- Biggest limitation: No evidence it extends lifespan or slows aging in healthy, non-deficient people.
- Genotype-dependent: The blood-pressure and homocysteine benefits only apply to the ~10–12% of people with the MTHFR 677TT variant.
- Cochrane is cautious: A 2025 review of all BP trials rated the evidence “very low certainty” overall because the studies were small and biased.
- Migraine dose is a megadose: 400 mg/day is ~250× the RDA, and long-term safety at that level is inferred, not fully studied.
What Is Riboflavin (Vitamin B2)?
Riboflavin is a water-soluble B-vitamin and the precursor to two coenzymes: flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). A coenzyme is a helper molecule that enzymes cannot work without — and riboflavin-derived FAD and FMN are among the hardest-working helpers in human biology. They are required by well over 100 enzymes, including the ones that run your mitochondrial electron transport chain (Complex I and Complex II), the enzyme MTHFR that regulates homocysteine, the fatty-acid oxidation enzymes that burn fat for energy, and glutathione reductase, which recycles your body’s master antioxidant.
The body cannot store much riboflavin. It is excreted in urine within hours, which is why you need a steady daily supply from food — eggs, dairy, lean meat, leafy greens, almonds, and fortified cereals — or from a supplement. The recommended dietary allowance (RDA) is 1.3 mg/day for men and 1.1 mg/day for women, and most people in developed countries meet it through diet. But as the next sections explain, “not deficient enough to cause disease” and “optimal for your particular genetics” are two different things.
How It Works
Riboflavin’s biology splits into two clean stories: one about energy and one about genetics.
The energy story (mitochondria). FAD sits at the very core of how your cells turn food into ATP, the energy currency of the body. FAD carries electrons inside Complex I (NADH dehydrogenase) and is a built-in part of Complex II (succinate dehydrogenase) — two of the five complexes that make up the mitochondrial electron transport chain. Without adequate riboflavin, that chain slows down, and every energy-hungry tissue — brain, heart, muscle — feels it. This is the mechanism behind riboflavin’s best-known clinical use: migraine. Researchers including Jean Schoenen proposed that migraineurs may have an underlying mitochondrial energy deficit, and that riboflavin, by feeding the respiratory chain, helps the brain keep up with its energy demands.
The genetics story (MTHFR). The enzyme methylenetetrahydrofolate reductase (MTHFR) — a key player in processing the amino acid homocysteine — uses FAD as its cofactor. A common inherited variant, MTHFR 677C→T, produces an enzyme that drops its FAD cofactor too easily, leaving it running at reduced capacity. The result: higher homocysteine and, in people with two copies of the variant (the “TT” genotype, found in roughly 10–12% of people of European descent), higher blood pressure and increased cardiovascular risk. Riboflavin, as the raw material for FAD, essentially “re-stabilizes” the faulty enzyme. This is a textbook example of a gene–nutrient interaction: the same modest dose of a vitamin does nothing for most people but measurably helps a specific genetic subgroup.
The Longevity Connection
🩸 Blood pressure and homocysteine — a gene-specific win. This is riboflavin’s most scientifically interesting claim, and it is entirely dependent on your MTHFR genotype. In the landmark 2006 study by McNulty and colleagues, 1.6 mg/day of riboflavin for 12 weeks lowered homocysteine by up to 22% — but only in people with the TT genotype (PMID 16380544). A 2013 randomized trial in treated hypertensive patients with the TT genotype found riboflavin lowered systolic blood pressure by 5.6 mmHg on top of their existing medications (PMID 23608654), and a four-year follow-up reported a drop of 9.2 mmHg systolic (PMID 22277556). The large JINGO study of 6,076 adults found that the TT genotype raised hypertension risk 1.42-fold, but that low riboflavin status combined with the TT genotype tripled the risk (PMID 33172445).
🧠 Migraine — the strongest human evidence, period. The 1998 randomized controlled trial by Schoenen remains the reference study: 400 mg/day of riboflavin for three months produced a 50% or greater reduction in attack frequency in 59% of patients versus 15% on placebo, with a number-needed-to-treat of just 2.3 (PMID 9484373). A later open-label study confirmed the effect — headache days fell from 4 to 2 per month (PMID 15257686). For a condition with few well-tolerated preventive options, that is a genuinely useful result, and it is the reason riboflavin appears in formal migraine guidelines as a preventive option.
🔋 Mitochondrial health — mechanistic but real. Riboflavin’s role in the respiratory chain is not just theory. In a rare inherited disease called riboflavin transporter deficiency (Brown-Vialetto-Van Laere syndrome), patients cannot move riboflavin into their cells, and they develop progressive muscle weakness and respiratory failure. Giving high-dose riboflavin rapidly reverses the symptoms (PMID 21110228) — a striking demonstration of how central this vitamin is to energy metabolism, and a reminder that “it’s just a B-vitamin” undersells it badly.
🧓 Brain aging and deficiency — observational only. Low B-vitamin status, including riboflavin, is common in older adults and is associated with poorer cognitive function and higher dementia risk in observational studies (PMID 41693429). Studies of elderly populations repeatedly find that a meaningful share have suboptimal riboflavin status (PMID 41263360). This is a plausible and important connection, but it is correlation, not causation — there is no randomized trial showing that riboflavin supplementation prevents cognitive decline in non-deficient people.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| Schoenen 1998 (PMID 9484373) | RCT, n = 55, 400 mg/day, 3 months | 59% of riboflavin patients vs 15% of placebo had ≥50% fewer migraine attacks (p = 0.002); NNT = 2.3. |
| Boehnke 2004 (PMID 15257686) | Open-label, 400 mg/day | Headache frequency fell from 4 to 2 days/month; abortive drug use dropped from 7 to 4.5 units/month. |
| McNulty 2006 (PMID 16380544) | RCT, n = 32 TT, 1.6 mg/day, 12 weeks | Homocysteine fell up to 22% in the MTHFR TT group (16.1 → 12.5 µmol/L, p = 0.003); no effect in CC/CT genotypes. |
| Wilson 2013 (PMID 23608654) | RCT, n = 91 treated hypertensives (TT), 1.6 mg/day, 16 weeks | Systolic BP fell 5.6 mmHg on top of existing antihypertensive drugs (p = 0.033). |
| Wilson 2012 (PMID 22277556) | 4-y follow-up, crossover, n = 31 TT | Riboflavin lowered systolic BP 9.2 mmHg (p = 0.001) and diastolic 6.0 mmHg (p = 0.003). |
| JINGO 2020 (PMID 33172445) | Observational, n = 6,076 adults | TT genotype raised hypertension risk 1.42-fold; TT + low riboflavin status tripled it (OR 3.00). |
| Cochrane 2025 (PMID 41123035) | Systematic review, 4 RCTs, 374 participants | Overall BP effect “very uncertain”: systolic −1.94 mmHg (p = 0.32), diastolic −3.03 mmHg (p = 0.04); high risk of bias. |
| Bosch 2011 (PMID 21110228) | Case series, riboflavin transporter deficiency | High-dose riboflavin rapidly reversed muscle weakness and biochemical abnormalities in this rare mitochondrial disease. |
| Rooney 2026 (PMID 41693429) | Narrative review | Low B-vitamin status (including riboflavin) is common in older adults and linked to cognitive decline — observational, not causal. |
| McNulty 2017 (PMID 27720779) | Review | Lays out the case for riboflavin as a personalized, genotype-targeted strategy for hypertension. |
Dosing and Safety
Riboflavin is unusual among supplements in that the “right” dose differs by a factor of 250 depending on what you are trying to achieve. There is no “longevity dose” — no trial has tested riboflavin for extending human lifespan.
| Goal | Dose | Notes |
|---|---|---|
| Prevent deficiency (RDA) | 1.3 mg/day (men), 1.1 mg/day (women) | Easily met through diet; a standard multivitamin covers this. |
| MTHFR TT — homocysteine / blood pressure | 1.6 mg/day | The exact dose used in the McNulty/Wilson trials. Only relevant if you are TT genotype (~10–12% of people). |
| Migraine prevention | 400 mg/day | The dose in the Schoenen and Boehnke trials; takes ~3 months to see full effect. |
| Riboflavin transporter deficiency | High dose, medically supervised | A rare genetic disease — not a self-treatment situation. |
Form and absorption: Riboflavin is best absorbed with food, and absorption saturates at roughly 25–30 mg per single dose — which is why the 400 mg migraine dose is usually split or relies on a slow-release formulation. Plain riboflavin (riboflavin-5′-phosphate is the body-ready form) is fine for most purposes.
Safety notes:
- Exceptional safety profile. Riboflavin is water-soluble and has no established tolerable upper intake level, because no toxicity has ever been demonstrated at reasonable doses. Excess is excreted in urine, turning it bright yellow — harmless and expected.
- Side effects are minimal. In the migraine trial, the only events were two cases of mild diarrhea and increased urination out of 55 participants — none serious (PMID 9484373).
- No meaningful drug interactions. Riboflavin does not significantly interact with common medications, which is part of why it is so appealing for migraine and hypertension add-on therapy.
- Long-term megadose data are thin. The 400 mg migraine dose has been used for years in clinical practice, but formal safety trials beyond a few months are limited.
❓ Common Questions About Riboflavin (Vitamin B2)
What is riboflavin (vitamin B2) and how does it work?
Riboflavin is a water-soluble B-vitamin that your body turns into two helper molecules called FAD and FMN. Those helpers power hundreds of enzymes, including the ones that make energy in your mitochondria, recycle your main antioxidant (glutathione), and run the MTHFR enzyme that keeps a harmful protein called homocysteine in check. Because you cannot store much riboflavin, you need it regularly from food or supplements.
What does the evidence actually show?
The strongest evidence is for two specific uses. First, high-dose riboflavin (400 mg a day) cuts migraine frequency in randomized trials — 59% of people improved by half or more, versus 15% on placebo. Second, a modest 1.6 mg a day lowers blood pressure and homocysteine specifically in people with two copies of a common MTHFR gene variant (about 10–12% of people). For general anti-aging in everyone else, there is only observational data, so we rate it 🥈 Silver overall — not a headline longevity molecule.
What’s the right dose?
It depends on your goal. To prevent deficiency, the RDA is 1.3 mg a day for men and 1.1 mg a day for women. For the MTHFR TT blood-pressure benefit, the trials used just 1.6 mg a day. For migraine prevention, trials used 400 mg a day — about 250 times the RDA. There is no proven longevity dose, and for most people there is no reason to megadose.
What are the risks and side effects?
Riboflavin is one of the safest supplements in existence. It is water-soluble, so your body simply excretes what it does not use — which is why your urine turns bright yellow. Even 400 mg a day in trials caused only occasional mild diarrhea or increased urination. There is no established toxic upper limit because no toxicity has ever been found at reasonable doses.
Who should avoid it?
Almost nobody needs to avoid riboflavin at normal doses; it has no meaningful drug interactions. Pregnant and breastfeeding women are safe at the RDA found in a prenatal vitamin but should not take 400 mg migraine doses, which have not been studied in pregnancy. As always, check with your doctor before starting any supplement.
The Bottom Line
The evidence hierarchy is clean and honest: riboflavin is a genuine, mechanistically well-understood nutrient with two real, randomized-trial-backed uses — migraine prevention (🥇 Gold, at 400 mg/day) and gene-specific blood-pressure and homocysteine lowering in MTHFR 677TT carriers (🥈 Silver, at just 1.6 mg/day). It is also essential for mitochondrial energy production, which a rare genetic disease demonstrates dramatically. That is a legitimate, evidence-based supplement story.
But it is not a longevity molecule. There is no randomized evidence that riboflavin slows aging or extends lifespan in healthy, non-deficient people, and a 2025 Cochrane review correctly cautions that even the blood-pressure evidence is “very low certainty” when pooled. The honest framing is this: if you are a migraine sufferer, or you know (from genetic testing) that you carry the MTHFR TT genotype, riboflavin is one of the cheapest and safest targeted interventions available. If you are neither, you almost certainly do not need to supplement it — your money and attention are better spent on interventions with broader evidence.
Who it’s for: migraine sufferers looking for a well-tolerated preventive option; people who have confirmed the MTHFR 677TT genotype and want to address the homocysteine/blood-pressure axis; and older adults with poor diets who may be marginally deficient. For everyone else, riboflavin is a “maybe in a multivitamin, not worth a dedicated pill” supplement — and that is exactly the kind of distinction this site exists to make.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Riboflavin is not approved to treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement, especially if you have high blood pressure, migraines, take prescription medication, or are pregnant or breastfeeding. Read our full disclaimer →
Sources
- Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998. PMID 9484373
- Boehnke C, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004. PMID 15257686
- McNulty H, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006. PMID 16380544
- Wilson CP, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin. Hypertension. 2013. PMID 23608654
- Wilson CP, et al. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012. PMID 22277556
- McNulty H, et al. Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: evidence from the JINGO project. BMC Med. 2020. PMID 33172445
- McNulty H, et al. Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension. Mol Aspects Med. 2017. PMID 27720779
- Rooney M, et al. Riboflavin supplements for blood pressure lowering in adults. Cochrane Database Syst Rev. 2025. PMID 41123035
- Bosch AM, et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD. J Inherit Metab Dis. 2011. PMID 21110228
- Hughes CF, et al. B vitamins, immune function and the ageing brain: a critical review of the evidence, mechanisms and potential role of the gut microbiome. Proc Nutr Soc. 2026. PMID 41693429
- Kirichenko A, et al. Iodine and vitamin status, body composition in older persons living in Republic of Sakha (Yakutia). Vopr Pitan. 2025. PMID 41263360
- Ward M, et al. Impact of the MTHFR C677T polymorphism on one-carbon metabolites: Evidence from a randomised trial of riboflavin supplementation. Biochimie. 2020. PMID 32330571